|COPE Homepage||Bottom of page||Previous entry:
Late response genes
for COPE Fund
[lymphokine-activated tumor inhibition] This is an experimental variant of the lymphokine mediated immunotherapy of tumors (see also: Adoptive immunotherapy) involving the use of LAK cells (lymphokine-activated killer cells).
This approach essentially involves local injections of low doses of IL2 into the tumor mass to induce non-reactive lymphocytes accumulated in the tumor mass to develop into reactive cells. A similar activation of cells has been observed also with the local injection of IL4 and immunoreactive peptide fragments of IL1.
Experimentally LATI has been successful in the treatment of poorly immunoreactive tumors.
Copyright © 2012 by H IBELGAUFTS. All rights reserved.
ENTRY LAST MODIFIED: January 2002
See REFERENCES for entry LATI.
Click BACKLINKS to see which COPE entries contain the term LATI .
|COPE Homepage||Top of Page|
|SUPPORT COPE | Santa Claus | Intro | Subdictionaries | New Entries | Contribute data | COPE Credentials|
|Support COPE with an educational grant. Please inquire|
| Access to COPE is free only for academic institutions and non-profit organizations. |
OTHER USERS: must contact COPE and pay a site licence fee.